Ciprofibrate: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026🚩 Report this page

Ciprofibrate

Fibrates

GB MHRA

Drug class: Fibrates
Availability: See label
Markets covered: 1
Products on record: 7

Overview

Ciprofibrate is an active pharmaceutical ingredient in the Fibrates group (C10AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	7	May 15, 2026

GBUnited Kingdom· MHRA

7 products

Uses

GBOfficial regulatory label· revised May 15, 2026[1]

g. exercise, weight reduction) for the following: − Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol. − Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.

How to take

Sources & citations

[1]MHRA (UK) · PL001421307 · revised May 15, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 15, 2026[1]

The adverse reactions observed in clinical studies and reported in post marketing experience are detailed below. Post-marketing adverse reactions are designated with a frequency “not known”.
Adverse reactions frequency is defined using the following convention:
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). Common Uncommon Rare Very rare Not known Blood and lymphatic system disorders Thrombocytopenia Nervous system disorders Headache Dizziness Somnolence Vertigo Respiratory thoracic and mediastinal disorders Pneumonitis Pulmonary fibrosis Gastrointestinal disorders Nausea Vomiting Diarrhoea Dyspepsia Abdominal pain Hepatobiliary disorders Liver function test abnormal Cholestasis Cytolysis Cholelithiasis Skin and subcutaneous tissue disorders Rash Alopecia Urticaria Pruritis Photosensitivity reaction Eczema Musculoskeletal and connective tissue disorders Myalgia Elevation of serum creatine phosphokinase Myopathy Myositis Rhabdomyolysis Reproductive system and breast disorders Erectile dysfunction General disorders and administration site conditions Fatigue Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised May 15, 2026[1]

Myalgia/myopathy − Patients should be advised to report unexplained muscle pain, tenderness or weakness immediately. CPK levels should be assessed immediately in patients reporting these symptoms. Therapy should be discontinued if myopathy is diagnosed or if markedly elevated CPK levels (levels exceeding 5 times the normal range) occur.
− Doses of 200 mg ciprofibrate per day or greater have been associated with a high risk of rhabdomyolysis. Therefore, the daily dose should not exceed 100 mg. 5). Use with caution in patients with impaired hepatic function. Periodic hepatic function tests are recommended (every 3 months for the first 12 months of treatment).
Ciprofibrate treatment should be discontinued in case of increased AST and ALT levels to more than 3 times the upper limit of normal or if cholestatic liver injury is evidenced. Secondary causes of dyslipidaemia, such as hypothyroidism, should be excluded or corrected prior to commencing any lipid lowering drug treatment.
5). If after a period of administration lasting several months, a satisfactory reduction in serum lipid concentrations has not been obtained, additional or different therapeutic measures should be considered. Excipients Ciprofibrate 100 mg tablets contain lactose.
Patients with rare hereditary problems of galactose intolerance, total lactose deficiency or glucose-galactose malabsorption should not take this medicine This medicine contains less than 1 mmol sodium (23 mg) per tablet that is to say essentially ‘sodium free’

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations